Full Text of PDF (367k)
Article in Japanese
Abstract
Case Report
Pembrolizumab-induced bullous pemphigoid in a patient with pulmonary pleomorphic carcinoma
Shun Mashimoto Hiromu Kawano Yuki Tsuneoka Maki Hasegawa Sho Yamashita Tomonobu Kawaguchi
Department of Respirology, Fukuoka Red Cross Hospital
ABSTRACT
This is the case of a 69-year-old man diagnosed with pulmonary pleomorphic carcinoma (Stage IIIb) who had a recurrence after chemoradiotherapy. The patient received pembrolizumab as a third-line treatment for high expression of PD-L1. Erythema and blisters were observed, and his skin biopsy showed bullous pemphigoid. The skin eruption improved after cessation of pembrolizumab and systemic corticosteroid therapy. Pembrolizumab was restarted after steroid tapering, and the antitumor effect persisted without relapse of skin findings. Although bullous pemphigoid is a relatively rare immune-related adverse event, consistently monitoring cutaneous symptoms for early detection is important.
KEYWORDS
Pembrolizumab Immune-related adverse event (irAE) Bullous pemphigoid (BP) Pulmonary pleomorphic carcinoma
Received 4 Mar 2021 ／ Accepted 14 Jul 2021
AJRS, 10(5): 411-414, 2021
Copyright © The Japanese Respiratory Society All Rights Reserved.